Introduction
The development of solid tumors is associated with the acquisition of genetic and epigenetic alterations and corresponding changes in gene expression that modify normal growth control and survival pathways. These changes may be brought about at the genomic level in a variety of ways, including, for example, altered karyotypes, point mutations and epigenetic mechanisms. It is now generally agreed that in order for a sufficient number of alterations to accumulate to cause a malignancy, one or more of the mechanisms that work to maintain genetic integrity in cells and/or to regulate cell cycle progression must be compromised, presumably through mutations that occur early in tumorigenesis (Loeb, 2001) . Genomic DNA copy number aberrations are frequent in solid tumors and are expected to contribute to tumor evolution by copy number-induced alterations in gene expression. A variety of cytogenetic and more recently array-based (Snijders et al., 2001) analytic methods have found a wide range in the number and types of chromosome level alterations present in human tumors, which are likely to reflect the many different solutions taken by individual tumors to escape normal protective mechanisms. These analyses also show that the genomes of established tumors are remarkably stable, as evidenced by the similarity of tumor recurrences with primaries (Waldman et al., 2000; Albertson, 2002) , indicating that the set of aberrations is maintained because of continued selective advantage. Taken together, these observations suggest that the spectrum of alterations that one sees in fully developed tumors is a composite of selection acting on the variation that is permitted to arise by the particular failures in genomic surveillance mechanism(s) present in the tumor. This leads, for example, to the expression of the same gene being altered in multiple ways in different tumors, or particular functional pathways being affected at different locations because certain genes in the pathways are more susceptible to alteration by the failures in genomic surveillance present in that tumor.
The interplay between selection and genetic instability in shaping tumor genomes is currently most clearly established in tumors with defects in mismatch repair (MMR). These tumor genomes show a high level of microsatellite instability because of failures in MMR genes (generally MSH2 or MLH1) either through mutation, as in tumors from patients with hereditary nonpolyposis colorectal cancer (Bocker et al., 1999) , or in sporadic tumors through silencing of MLH1 (Esteller, 2000) . The MMR-deficient colorectal tumors also differ from MMR-proficient tumors in their histology (Bocker et al., 1999) , in the genes that are inactivated in the tumors (Zhang et al., 2001; Duval and Hamelin, 2002) , in their response to therapy (Aebi et al., 1996; Fink et al., 1998) and by the relatively low number of chromosomal level alterations in their genomes (Muleris et al., 1990 Remvikos et al., 1995; Schlegel et al., 1995; Eshelman et al., 1998; Soulie et al., 1999) . Thus, MMRdeficient tumors can be readily distinguished from MMR-proficient tumors based on the types of genetic instability they display and the resultant selection for alterations in those critical genes that are susceptible to mutation through microsatellite instability.
The relation of mechanistic defect to aberration type has not been established for most sporadic tumor types, but it is likely that some of the variety and complexity associated with these tumor genomes might be rationalized if associations could be developed between particular aberrations and specific defects in maintenance of genome stability. The recently developed highthroughput array-based genome scanning techniques such as microarray-based comparative genomic hybridization (CGH) now offer the means to analyse many tumor genomes and to more precisely define their genomic alterations. The higher resolution and precision afforded by these measurements provide the opportunity to develop approaches to the interpretation of DNA copy number alterations that recognize particular types of genetic instability. Here, we demonstrate this possibility with a study of the genomic effects of MMR competence. Although it has been known for some time that tumors with defects in MMR show few chromosome level changes compared to most sporadic solid tumors as measured by cytogenetics, flow sorting and chromosome CGH, the data we present here not only confirm the earlier cytogenetic analyses, but also reveal that there are differences in aberration frequencies associated with the particular MMR gene defects. In order to investigate the effect of MMR competence on genome evolution in more detail, we extended these analyses to a model system in which we could repeatedly evaluate the genomic changes arising in response to selection for resistance to a single agent in cell populations with defined genetic backgrounds. The analysis of multiple independent methotrexate-resistant cell pools revealed differences in aberrations associated with MMR-proficient and -deficient HCT116 cells. Furthermore, they showed that when copy number changes were present, they included plausible drug resistance target genes, indicating that the frequency of aberrations that could be considered bystanders was low. These studies provide a model system and framework for further aberration-based classification of tumor genomes.
Results

Copy number aberrations in MMR-deficient and -proficient cell lines
Cytogenetic analyses have shown that tumors with defects in MMR have fewer chromosomal changes than most solid tumors, suggesting that a greater proportion of the alterations required for malignancy occur in genes whose nucleotide sequences are susceptible to errors normally corrected by this system. Here, we used genome-wide array CGH (Snijders et al., 2001 ) to carry out a higher resolution evaluation of the effect of MMR competence on the genomic alterations occurring in 10 MMR-deficient cell lines (complete data sets available at: http://cc.ucsf.edu/albertson/public/) compared to 10 MMR-proficient cell lines (Snijders et al., 2001) . We counted the number of gains or losses of whole chromosomes, which might be expected to occur following failures of karyokinesis or cytokinesis, and the number of copy number transitions within a chromosome, which are likely to reflect DNA strand breakage that led to nonreciprocal translocations. We also distinguished two types of focal aberrations, those involving low-level gains or losses of DNA sequence spanning one to two clones and gene amplifications, which we defined as focal high-level copy number changes ( Figure 1a) . We found few copy number alterations in MMR-deficient cells (Figure 1b) . The MMR-deficient cells showed significantly fewer aberrations of all types compared to MMR-proficient cells (Figure 2 ) in accord with earlier observations, although we observed a substantial number of aberrations in some MMR-deficient lines. We also found a dependence of aberration type on the specific MMR defect. Cells deficient in MLH1 had a higher frequency of copy number transitions and focal aberrations than MSH2-deficient cells (Figure 2 ).
Copy number aberrations in methotrexate-resistant MMR-deficient and -proficient cells
We further investigated the influence of MMR competence on genome evolution, by analysing the copy number changes that occurred in multiple independent populations of methotrexate-resistant cells arising in MMR-deficient and -proficient cells. We chose methotrexate resistance as the model system, because clinical resistance to methotrexate targets a number of genes by a variety of mechanisms, including mutations at the nucleotide level and gene amplification (see below), thereby providing the opportunity to determine which types of aberration occur more frequently in MMRdeficient and -proficient backgrounds. We used MMRdeficient HCT116 (MLH1À) and HCT116 þ chr3 cells made MMR proficient by introduction of chromosome 3 carrying a wild-type copy of MLH1 (Koi et al., 1994; Hawn et al., 1995) . Array CGH analysis of the HCT116 þ chr3 cells indicated that they carry an additional copy of most of 3p (Figure 3a, b) . Fluorescent in situ hybridization (FISH) with probes to 3p and 3q confirmed the presence of two normal copies of chromosome 3 and an additional telocentric chromosome showing only hybridization to the 3p probe (data not shown). Slightly elevated copy numbers of chromosomes 12p and 15 are also evident, indicating additional copies in a minority of the cells (Figure 3a) .
Genome-wide analysis of copy number aberrations in methotrexate-resistant cell pools (Figure 4 ) indicated 
Figure 2 that MMR-deficient HCT116 cells most frequently showed no copy number aberrations (16/29 pools). If copy number aberrations were present, they involved loss or gain of whole chromosomes, including loss of one copy of chromosome 21 (9/29 pools, Figure 3c ), or gain of a copy of chromosome 5 (4/29 pools, Figure 3d ). We rarely observed aberrations involving partial chromosome arms (five copy number transitions/29 pools). In contrast to a previous report (Lin et al., 2001) , we observed no amplifications of DHFR, even when the level of methotrexate used for selection was increased from 25 to 100 nm (data not shown).
A different spectrum of aberrations occurred in MMR-proficient HCT116 þ chr3 cells. All resistant cell pools showed aberrations involving chromosome 5 ( Figure 4 ). Most frequently, we observed amplicons (7/ 13 pools) centered at the DHFR locus and/or a neighboring B13 Mb region flanked by RP11-174I22 and RP11-172K14 that mapped proximal to DHFR ( Figure 5 ). These recurrent amplicons did not include HMGCR, previously reported to be coamplified with DHFR in methotrexate-resistant cells (Srimatkandada et al., 2000) . We also observed that the copy number profile for all of chromosome 5, as well as within the amplified region was unique to each resistant cell pool. For example, in three cases there were losses of portions of 5q distal to the amplicon, but the extent of the deleted region varied. In other cases, a gain of all or a portion of 5q was present in addition to the amplicon(s). In the resistant HCT116 þ chr3 cell pools without amplification, we observed gains of chromosome 5 or 5q (6/l3 pools) together with a loss of distal chromosome 21 in one case (Figure 4 ). We observed a nonrecurrent pattern of aberrations in one resistant cell pool, which included a gain of distal 5q and loss of chromosome 18 (Figure 4) . In contrast to MMR-deficient cells, we observed a higher frequency of aberrations involving partial chromosome arms (seven copy number transitions/13 pools, excluding copy number changes on chromosome 5 when amplifications were present).
Since studies of the organization of amplicons by cytogenetics indicate that the amplified DNA may be present in multiple copies on a chromosome, often visualized as a homogeneously staining region or, it may be present as free circular or linear structures, double minutes (Guan et al., 1996; Singer et al., 2000) , we examined metaphase spreads from several resistant cell pools using FISH with probes for chromosome 5. We observed rearrangements involving the DHFR locus on this chromosome (data not shown), but found no evidence of double minutes, in contrast to a previous report of amplification of DHFR in methotrexateresistant HCT116 þ chr2 cells (Lin et al., 2001) . The differing observations may be because of the selection protocols employed or to subtle differences in the HCT116 cells used in the two studies. We note that since HCT116 is MMR deficient, the cells are highly susceptible to continuing mutation in microsatellite sequences. Thus, the genetic backgrounds of HCT116 cell cultures may vary, resulting in different types of genomic alterations providing the most effective drug resistance. A5  A10  A11  B2  B3  B6  B8  C3  C6  I2  I7  O1  O3  O4  O5  Q1  Q2   E1   HCT116+chr3   E2  E3  E4  K1  K5  L1  M1  M2  M3  P2  R1  R2   11  12  13  10  14  15  16  17  22  X  18  19 
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Glu Figure 6 Schematic overview of methotrexate metabolism. Two separate systems, the high-affinity folate receptors (FOLR, not shown) and the reduced folate carrier (SLC19A1) maintain intracellular levels of folate cofactors essential for the synthesis of nucleotides. The reduced folate carrier is the major route by which methotrexate (MTX) is transported into the cell (Matherly, 2001) . Once inside the cell, folylpolylglutamate synthetase (FPGS) catalyzes addition of glutamic acid residues (GLU) to MTX and folates, causing them to be retained within the cell (Rots et al., 1999; Takemura et al., 1999; Turner et al., 2000) . Although glutamylation of methotrexate does not affect affinity for the target enzyme dihydrofolate reductase (DHFR), in many cases the modified folate is a better enzyme substrate (Rots et al., 1999; Turner et al., 2000) . Inhibition of DHFR leads to reduction in deoxythymidine triphosphate and purine nucleotides, causing misincorporation of uracil by DNA polymerase under the resulting conditions of limiting nucleotides. Subsequently, DNA strand breaks may result from cycles of removal and reincorporation of uracil or other misincorporated nucleotides because of imbalances in nucleotide pools (Frouin et al., 2001) . MTX can be effluxed from cells by energy-dependent pumps (ABCC1-4) after removal of GLU residues (Zeng et al., 2001; Chen et al., 2002) by GGH (Cole et al., 2001) . Clinical and experimental resistance to MTX has been reported to involve alterations in the activity of a number of the proteins encoded by these genes. Downregulation of the reduced folate carrier encoded by SLC19A1 may be accomplished by mutations in the gene, aberrant mRNA splicing, deletions, translocations leading to transcriptional silencing and increased rate of turnover (Matherly, 2001 ). Modifications of DHFR activity in MTX-resistant cells include upregulation of expression by increased DNA copy number, promoter mutations and amplification of mutant DHFR with low affinity for MTX (Banerjee et al., 2002) . Inefficient polyglutamylation of methotrexate has also been reported in resistant cells because of low levels of FPGS activity (Rots et al., 1999; Takemura et al., 1999) and in some cases high levels of activity of GGH (Cole et al., 2001 ). However, polyglutamylation of folates is necessary for cell proliferation. Some resistant cells have been reported to have high levels of folates, which may not only compensate for inefficient polyglutamylation, but may also contribute to resistance by competition with methotrexate (Takemura et al., 1999) . In contrast, the efflux pumps (ABCC1-4) are expected to contribute little to resistance in the presence of continuous MTX treatment (Zeng et al., 2001; Chen et al., 2002) , since polyglutamylated MTX cannot be transported, although they may contribute to resistance in the presence of low MTX levels. Increased activity could also result in greater efflux of folates, thereby rendering cells more sensitive by reducing folate competition with methotrexate. Chromosomal locations of genes are shown in parentheses
Shaping of tumor and drug resistant cell genomes AM Snijders et al upregulation of g-glutamate hydrolase (GGH) on chromosome 8q12 (Cole et al., 2001) . Since methotrexate-resistant MMR-deficient HCT116 cells displayed few induced copy number changes, we do not know which gene functions have been altered in the resistant cells, but expect that nucleotide level changes may have occurred in certain genes. However, the recurrent copy number changes that did occur were consistent with downregulation of drug influx by loss of one copy of the reduced folate carrier (chromosome 21 loss, 9/29 pools) or upregulation of DHFR (chromosome 5 gain, 4/29 pools). In contrast, we found that the major mechanism of resistance in HCT116 þ chr3 was upregulation of DHFR, most often by amplification. Thus, MMRproficient and -deficient HCT116 cells responded differently to challenge by methotrexate. The observed high frequency of amplifications in MMR-proficient cells, and lower frequency of copy number aberrations in MMR-deficient cells is consistent with the previously described observations in MMR-proficient and -deficient cell lines ( Figure 2 ) and with published data on tumors (Muleris et al., 1990 Remvikos et al., 1995; Schlegel et al., 1995; Eshelman et al., 1998; Soulie et al., 1999) . We observed two regions of amplification on 5q. One was centered on DHFR, the known methotrexate target. The other mapped to a more proximal locus and no previously identified methotrexate-resistant gene maps within the B13 Mb region defined by the amplicon boundaries. However, CCNB1, which maps within this region is a candidate, since upregulation of CCNB1 because of increased copy number could facilitate progression of MMR-proficient cells through G2/M by overcoming a p53-mediated arrest elicited in response to methotrexate-induced DNA damage (Innocente et al., 1999; Krause et al., 2000; Frouin et al., 2001; Taylor and Stark, 2001) . Thus, this analysis may have identified another methotrexate resistance gene(s), which is important in the context of functional MMR. However, we cannot rule out the possibility that the copy number profile reflects selection for increased copy number of features of the genome important for DHFR amplicon formation or maintenance (e.g. replication origins).
Gene amplification has been studied in vitro in a variety of systems by selection for cells capable of growth in the presence of certain drugs or in mouse models susceptible to gene amplification. These studies indicate that gene amplification is initiated by a DNA double-strand break, and that it occurs in cells that are able to progress inappropriately through the cell cycle with this damaged DNA (Kuo et al., 1994; Coquelle et al., 1997; Chernova et al., 1998; Paulson et al., 1998; Pipiras et al., 1998; Zhu et al., 2002) . In some cases amplicon boundaries have been mapped to recurrent locations coincident with experimentally induced double-strand breaks or common chromosomal fragile sites (Kuo et al., 1994 Hellman et al., 2002) , which are 200-300 kb regions often associated with a high frequency of recombinogenic events, including recurrent chromosome aberrations associated with various cancers (Sutherland, 1991; Sutherland and Richards, 1995; Sutherland et al., 1998) . In our studies, we found that the amplicons generated in the HCT116 þ chr3 cells were all unique. Thus, our data provide no evidence that a common initiating site of breakage contributed to their initiation. Instead, it appears more likely that amplification was initiated by random double-strand breaks subsequent to misincorporation of nucleotides in the presence of methotrexateinduced imbalance in nucleotide pools.
In both MMR-proficient and -deficient drug-resistant cells, we observed a few copy number aberrations, that occurred in only one cell pool and that did not involve genomic regions currently known to harbor resistance genes. These aberrations might be considered bystanders that do not themselves confer resistance. They could be participants in chromosomal rearrangements that resulted in the required alteration of gene expression on the partner chromosome, or nonfunctional aberrations captured by chance in the resistant cells. On the other hand, they may represent less frequent solutions to overcome inhibition by methotrexate that may be favored in certain circumstances, or they may reveal previously unrecognized mechanisms of drug resistance. For example, in one cell pool, we observed copy number alterations affecting the methotrexate metabolic pathway at three different sites. These cells gained chromosome 5 and lost 21. In addition, they gained a copy of distal 9q including FPGS, which is perhaps unexpected, since it is likely to increase efficiency of polyglutamylation and thus retention of methotrexate in the cells. However, this constellation of changes may provide an optimal balance of activities that promote methotrexate resistance through reduced drug influx (loss of 21) and increased copy number of DHFR, while at the same time ensuring that sufficient levels of polygluytamated folates are present for cell proliferation (Takemura et al., 1999; Cole et al., 2001 ). These observations have implications for the interpretation of aberrations in tumor genomes, since they suggest that most genomic alterations are likely to contribute to the neoplastic process, and only rarely are they bystanders.
Methotrexate resistance appears to be achieved by a multistep selection process, as evidenced by the presence of alterations in several genes, as well as the chromosome 5 amplicons in MMR-proficient cells. Thus, significant selection is operating on subtle adventitiously arising genomic alterations, each one of which may slightly enhance the viability of the cells. A similar accumulation of subtle events is likely to be involved in tumorigenesis. Models of human cancer highlight the importance of upregulation of growth-promoting genes together with downregulation of apoptotic signaling. By altering the expression of a small number of carefully chosen genes, it is possible to experimentally generate transformed cells or tumors that display almost all aspects of the tumor phenotype, including invasion, metastasis and angiogenesis (Zimonjic et al., 2001; Pelengaris et al., 2002) . One feature of human cancers that is not recapitulated in these models is the frequent and varied alterations that occur in the genomes of cells in solid tumors. This apparent increased complexity is likely to reflect the contribution of genome rearrangements to the evolutionary selection for incremental changes in gene expression that promote cell proliferation and survival in human tumors, in contrast to the well-considered choices made when manipulating mouse models and cultured cells. Thus, as cells tiptoe toward malignancy, DNA copy number changes provide one mechanism by which cells can seek the solutions that are just right for competitive advantage, with the result that their genomes are shaped both by selection for beneficial changes in gene expression and by failures in maintenance of genomic integrity that allow certain types of aberration to occur with higher probability.
Materials and methods
Cell lines
We obtained DU145, SKOV3, HCT116, AN3CA and SKUT1 from the UCSF Cell Culture Facility, and Jurkat, LoVo, DLD-1, LS174 T and SW48 from the American Type Culture Collection (ATCC, Manassas, VA, USA). Dr CR Boland generously provided the MMR-proficient cell line HCT116 þ chr3 (Koi et al., 1994; Hawn et al., 1995) , containing a wild-type copy of MLH1. We confirmed the presence of mlh1 protein by Western blot. We did not use a companion cell line, HCT116 þ chr2, which others have used (Lin et al., 2001) , because our array CGH analysis of the cell line revealed a single copy gain of chromosome 21 and no evidence of additional chromosome 2 material. The complete data set is available at: http://cc.ucsf.edu/albertson/public/.
Cell culture and selection of resistant cell pools
We maintained HCT116 and HCT116 þ chr3 in DMEM supplemented with 4.5 g/l. glucose, 0.584 g/l l-glutamine, 3.7 g/l NaHCO 3 , 10% dialyzed fetal bovine serum (HyClone, UT), 1 Â penicillin and 1 Â nonessential amino acids. We supplemented the media for HCT116 þ chr3 with 400 mg/ml geneticin disulfate. We dissolved methotrexate (Sigma) in 0.1 m NaOH and diluted it to 100 or 500 mm in Hank's BSS. We challenged cells with methotrexate using five different protocols for setting up the cultures in order to increase the probability that resistant cell pools arose as independent events. For protocol 1, we seeded 4 Â 10 5 cells in 100 mm plates (pools O1-O5, P2) or T75 flasks (protocol 2, pools 4-11, E1-4, K1, K5, L1, M1-3, Q1, Q2, R1 and R2) and allowed cells to recover overnight before changing to fresh medium containing 25 nm methotrexate. We also seeded 3 Â 10 3 cells (protocol 3, pools A-C) or 100 cells (protocol 4, pools I2 and I7) in each well of multiwell plates, expanded the cells in each well to 4 Â 10 5 cells and then transferred them to T75 flasks. We allowed the cells to recover overnight before changing to medium containing 25 nm methotrexate. For protocol 5 (pools 1-3), we seeded 10 4 cells in each of three wells of a 24-well plate and allowed the cells to recover overnight before changing to medium containing 25 nm methotrexate. In all cases, we changed the medium every 2-3 days until resistant colonies arose (2-3 weeks). We pooled the resistant colonies from each flask or plate or isolated a single resistant colony (pools O1-O5 and P2) and expanded them in media containing 25 nm methotrexate. Resistant colonies arose in HCT116 cultures at B50 times higher frequency than in HCT116 þ chr3 cultures (142764/400 000 cells compared to 2.871.4/400 000 cells).
In several cases, we compared the copy number profiles obtained from individual colonies isolated from a flask with the pool of cells from the same flask. Since the same genomic aberrations were observed in both, indicating a common progenitor, the analyses of cell pools were considered equivalent to individual isolated clones. We verified by array CGH that the copy number profiles of genomic DNA from cells cultured in parallel, but not treated with methotrexate, remained stable. In addition, we analysed TP53 mutation status, by sequencing exons 2-11 in untreated HCT116 and HCT116 þ chr3 cells used to seed plates for selection of resistant pools O and P, resistant HCT116 cell pools O1 and O4 and HCT116 þ chr3 pools M1-M3, P2, R1 and R2. In all cases, the sequence was wild type.
DNA isolation
We incubated cells from a T75 flask overnight at 551C in a 3 ml solution containing 0.01 m Tris, pH 7.5, 0.001 m EDTA, pH 8, 0.5% SDS and 0.1 mg/ml proteinase K. We precipitated the DNA with ethanol, recovered it by spooling and then dissolved it in B300 ml H 2 O.
DNA labeling
We labeled genomic DNA by random priming in a 50 ml reaction by combining 300 ng genomic DNA, 1 Â random primers solution (BioPrime DNA Labeling System, Gibco BRL), 1 Â dNTP solution (0.2 mm. each of dATP, dTTP, dGTP, 0.05 mm dCTP, 1 mm Tris base (pH 7.6), 0.1 mm EDTA), 40 mm Cy3 or Cy5-dCTP (Amersham) and 40 U Klenow fragment (BioPrime DNA Labeling System, Gibco BRL). We incubated the DNA and the random primers in a volume of 42 ml at 1001C for 10-15 min, placed the reaction on ice and added the dNTP solution, labeled nucleotides and Klenow fragment. We incubated the random priming reaction overnight at 371C. We removed unincorporated nucleotides using a Sephadex spin column.
BAC arrays
We used two versions of the whole genome human BAC arrays described previously (Snijders et al., 2001) . Each array is comprised of 2464 clones printed in triplicate. HumArray1.14 (Snijders et al., 2001) contains 2277 clones that map to a single site in the genome by FISH. HumArray2.0 is the nextgeneration genome array and contains 2443/2464 clones that can be mapped onto the genome sequence. To generate HumArray2.0, we removed multisite clones and clones that mapped improperly from HumArray1.14 and added others to improve coverage.
We assembled an array providing higher density coverage of the DHFR region at 5q14 by arraying an additional 10 BACs from the region. We obtained a total of 13 BACs from the RP11 library from Dr N Nowak (Roswell Park Cancer Institute) and from the CTC and CTD libraries from Invitrogen. We mapped each BAC onto metaphase chromosomes by FISH to confirm that it mapped to a single location at 5q14 and excluded three BACs because they mapped to multiple sites in the genome. We also included 200 clones distributed across the genome on the array. We used these clones for normalization, so that hybridization ratios from the DHFR array could be compared to the genome-wide data obtained on HumArray2.0.
Array CGH hybridization
We combined and precipitated 50 ml Cy3 labeled test DNA, 50 ml Cy5 labeled reference DNA and 100 mg human Cot-1 DNA by adding 0.1 volumes of 3 m sodium acetate (pH 5.2) and two volumes of ice-cold ethanol. We collected the precipitate by centrifugation and dissolved the pellet in a final hybridization mixture containing 50% formamide, 2 Â SSC and 4% SDS. We denatured the hybridization mixture at 751C for 10-15 min and then incubated the samples at 371C for 1 h to block repetitive DNA sequences.
We applied a ring of rubber cement closely around the array to form a well, into which we added 50 ml of a preincubation solution containing 250 mg salmon sperm DNA, 50% formamide, 2 Â SSC and 4% SDS. After a 30 min incubation at room temperature, we removed B30 ml of the preincubation solution and added the denatured and reannealed hybridization mixture. We placed a silicone gasket around each hybridization area, placed a microscope slide on top of the gasket, which was thick enough to prevent the microscope slide from contacting the hybridization solution and clamped the whole unit together using binder clips to create an air-tight environment. We carried out the hybridization to the arrays for B48 h on a slowly rocking table at 371C. After disassembling the hybridization chamber, we rinsed off the excess hybridization fluid with PN buffer (PN: 0.1 m sodium phosphate, 0.1% nonidet P40, pH 8), then washed the arrays once in a solution containing 50% formamide in 2 Â SSC for 15 min at 451C and finally in PN buffer at room temperature for 15 min. Subsequently, we removed the ring of rubber cement, drained excess liquid from the arrays, mounted them in a solution containing 90% glycerol, 10% PBS and 1 mm DAPI, and sealed them with a cover slip.
Imaging and analysis
We acquired 16 bit 1024 Â 1024 pixel DAPI, Cy3 and Cy5 images using a custom built CCD camera system (Pinkel et al., 1998) . We used 'UCSF SPOT' software (Jain et al., 2002) to automatically segment the spots based on the DAPI images, perform local background correction and to calculate various measurement parameters, including log 2 ratios of the total integrated Cy3 and Cy5 intensities for each spot. We used a second custom program SPROC to associate clone identities and a mapping information file with each spot, so that the data could be plotted relative to the position of the BACs on the August, 2001 freeze of the draft human genome sequence (http://genome.ucsc.edu). SPROC also implements a filtering procedure to reject data based on a number of criteria, including low reference/DAPI signal intensity and low correlation of the Cy3 and Cy5 intensities with a spot. The SPROC output consists of averaged ratios of the triplicate spots for each clone, standard deviations of the triplicates and plotting position for each clone on the array, as well as other clone information stored in the database, such as STS content. We edited the data files to remove ratios on clones for which only one of the triplicates remained after SPROC analysis and/ or the standard deviation of the log 2 ratios of the triplicates was 40.2.
Statistical methods
For a given sample, we identified copy number transitions on the chromosomes by applying unsupervised Hidden Markov Model methodology (Rabiner, 1989) to discover spatially coherent homogeneous groups of clones with the same underlying copy number. We merged adjacent stretches consisting of more than two contiguous clones assigned to the same state if the medians of these stretches were not sufficiently different (the absolute difference less than 0.2) or if the medians of both stretches were close enough to 0 in their absolute values (o0.25). If a chromosome contained N stretches, we recorded (NÀ1) transitions and arbitrarily placed the transition points at the last clone of the first of the two adjacent stretches. We identified whole chromosomes as gained or lost depending on the value of their median, if they contained no transitions and their absolute median was greater than 0.25. We recorded single clones or pairs of clones as focal aberrations if their values were further away from the median of the corresponding stretch than four times the median absolute deviation of that stretch. Finally, we counted a clone or a group of clones as a focal amplification if (a) the values of the log 2 ratios were greater than 1 and (b) the region containing clones with elevated ratios (log 2 ratio 40.7) only spanned o10 Mb.
We used the Wilcoxon rank-sum test to assess the significance of the differences between groups.
